Table 1.
Sociodemographic, Clinical, and Treatment Characteristics at Baseline
| STRIDE Intervention N = 50 | Medication Monitoring N = 50 | Full Sample N = 100 | |
|---|---|---|---|
| Mean (Standard Deviation) | |||
| Age (years; range = 31–81) | 57.2 (10.6) | 54.9 (11.2) | 56.1 (10.9) |
| Months on AET (AET start to enrollment) | 17.70 (8.87) | 18.13 (8.49) | 17.91 (8.64) |
| N (%) | |||
| Gender | |||
| Women | 50 (100) | 50 (100) | 100 (100) |
| Race | |||
| White | 47 (94) | 44 (88) | 91 (91) |
| Asian | 0 (0) | 4 (8) | 4 (4) |
| Black or African American | 1 (0) | 0 (0) | 1 (1) |
| Other | 1 (2) | 2 (4) | 3 (3) |
| Not Reported | 1 (2) | 0 (0) | 1 (1) |
| Ethnicity | |||
| Hispanic or Latino/a | 1 (2) | 2 (4) | 3 (3) |
| Not Hispanic or Latino/a | 47 (94) | 47 (94) | 94 (94) |
| Not Reported | 2 (4) | 1 (2) | 3 (3) |
| Education | |||
| Advanced Professional Degree | 3 (6) | 6 (12) | 9 (9) |
| Master’s Degree | 16 (32) | 16 (32) | 32 (32) |
| College Graduate | 19 (38) | 15 (30) | 34 (34) |
| Some college/Technical School | 9 (18) | 7 (14) | 16 (16) |
| High school graduate/GED | 3 (6) | 5 (10) | 8 (8) |
| 11th grade or less | 0 (0) | 1 (2) | 1 (1) |
| Relationship Status | |||
| Married/Cohabitating | 38 (76) | 35 (70) | 73 (73) |
| Non-cohabitating relationship | 1 (2) | 2 (4) | 3 (3) |
| Single, never married | 5 (10) | 4 (8) | 9 (9) |
| Divorced/separated | 6 (12) | 6 (12) | 12 (12) |
| Loss of long-term partner/widowed | 6 (12) | 3 (6) | 9 (9) |
| Employment Status | |||
| Full-time/part-time work or student | 33 (66) | 29 (58) | 62 (62) |
| Caring for home or family | 4 (8) | 6 (12) | 10 (10) |
| Unemployed | 1 (2) | 3 (6) | 4 (4) |
| Not working due to illness/disability | 0 (0) | 2 (4) | 2 (2) |
| Retired | 9 (18) | 9 (18) | 18 (18) |
| Other or missing | 3 (6) | 2 (4) | 5 (5) |
| Income | |||
| $25,000-$49,999 | 2 (4) | 5 (10) | 7 (7) |
| $50,000-$99,999 | 11 (22) | 11 (22) | 22 (22) |
| $100,000-$149,999 | 9 (18) | 9 (18) | 18 (18) |
| > $150,000 | 27 (54) | 23 (46) | 50 (50) |
| Declined to respond | 1 (2) | 2 (4) | 3 (3) |
| Breast Cancer Stage | |||
| Stage 0 | 5 (10) | 3 (6) | 8 (8) |
| Stage I | 36 (72) | 41 (82) | 77 (77) |
| Stage II | 6 (12) | 10 (20) | 16 (16) |
| Stage III | 3 (6) | 2 (4) | 5 (5) |
| Type of AET | |||
| Aromatase Inhibitor | 28 (56) | 32 (64) | 60 (60) |
| Tamoxifen | 22 (44) | 18 (36) | 40 (40) |
| Primary Treatment Type | |||
| Surgery only | 10 (20) | 13 (26) | 23 (23) |
| Surgery & Radiation | 25 (50) | 23 (46) | 48 (48) |
| Surgery & Chemotherapy | 2 (4) | 6 (12) | 8 (8) |
| Surgery, Chemotherapy, & Radiation | -- | 8 (16) | 21 (21) |
| Node Status | |||
| Node Positive | 10 (20) | 12 (24) | 22 (22) |
| Node Negative | 36 (72) | 34 (68) | 70 (70) |
| Not Evaluated | 4 (8) | 4 (8) | 8 (8) |
| Menopausal Status | |||
| Pre- or Peri-menopausal | 18 (36) | 18 (36) | 36 (36) |
| Post-menopausal | 25 (50) | 23 (46) | 48 (48) |
| Not Reported | 7 (14) | 9 (18) | 16 (16) |
| HER2/neu Status | |||
| HER2/neu Positive | 5 (10) | 8 (16) | 13 (13) |
| HER2/neu Negative | 40 (80) | 40 (80) | 80 (80) |
| Not Reported | 5 (10) | 2 (4) | 7 (7) |
| Ovarian Suppression | |||
| Receiving Ovarian Suppression | 8 (16) | 20 (40) | 28 (28) |
| Not Receiving Ovarian Suppression | 42 (84) | 30 (60) | 72 (72) |
*
Note: AET = Adjuvant Endocrine Therapy